All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

March 12th 2025

Treatment with casdatifan was well tolerated and showed meaningful clinical activity in patients with previously treated ccRCC.

Investigators Are Making Headway Bringing CAR T-Cell Therapy to Solid Tumors

March 12th 2025

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer

March 12th 2025

The FDA granted orphan drug designation to rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from lung cancer.

Fox Chase Cancer Center’s Biosample Repository Receives Reaccreditation From College of American Pathologists

March 12th 2025

Fox Chase Cancer Center’s Biosample Repository Facility was recently awarded reaccreditation by the College of American Pathologists based on the results of an on-site inspection.

Maintenance OSE2101 Plus FOLFIRI Meets Primary OS End Point in Advanced/Metastatic PDAC

March 12th 2025

Maintenance treatment with OSE2101 plus FOLFIRI after FOLFIRINOX induction chemotherapy displayed positive topline results in advanced/metastatic PDAC.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

March 12th 2025

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

March 12th 2025

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

HCP Survey Outlines Challenges, Strategies for Venetoclax Initiation in CLL in the Community Setting

March 12th 2025

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML

March 12th 2025

The γδ T-cell agent INB-100 demonstrated a 100% relapse-free survival rate in patients with AML.

BOVen Regimen Is Safe and Effective in First-Line TP53-Mutated MCL

March 11th 2025

BOVen met the primary end point of 2-year PFS in a phase 2 study, displaying high response rates in treatment-naive TP53-mutated MCL.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

March 11th 2025

SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.

SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors

March 11th 2025

The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.

Moffitt Study Identifies Immune Response That May Stop Breast Cancer from Spreading

March 11th 2025

A new Moffitt Cancer Center study has identified a specific immune response that may prevent the spread of breast cancer cells within the body.

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

March 11th 2025

Vepdegestrant improved PFS in ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer, but PFS was not improved in the ITT population.

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC

March 11th 2025

Amivantamab plus lazertinib was approved in Canada for first-line EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

March 11th 2025

Cema-cel generated CRs, most of which were durable, among patients with relapsed/refractory LBCL who were naive to anti-CD19 CAR T-cell therapy.

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma

March 11th 2025

Cemiplimab-based therapy is effective and has a safety profile consistent with prior reports in locally advanced/metastatic penile cancer.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer

March 10th 2025

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.